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ABSTRACT 
 
Background 
Head and Neck cancers account for 3% of all newly discovered cancers 
metastatic carcinoma within cervical lymphnodes with an unknown primary tumour 
site accounts for 3-5% of all head and neck cancers, this highlights the need for proper 
systematic screening and management of  secondaries  neck with unknown primaries.  
Objectives. 
The most common histopathological type common in our population and the 
age and sex incidence of the malignant cervical lymphadenopathy with an unknown 
primary, the staging of the disease, interpretation of possible site of primary based on 
nodal involvement and various  investigations  to identify the primary site and ideal 
treatment modality for the patients studied and  reported  
Methodology 
Patients with malignant  cervical lymhadenopathy  are diagnosed  in 
department of General Surgery at Government Royapettah hospital.43 of them are to 
be selected, detailed history is elicited from the patient thorough  clinical examination 
of the patient is done and disease staged according to TNM Classification. FNAC   / 
histopathological study of the tumour is done and age and sex incidence  of disease 
also done 
Results 
The results of the study like histopathological types, age and sex incidence of 
diseases and topographical distribution of disease are identified and put on the tables 
  
Conclusion 
With all the available investigations the unknown primary sites were being 
tried to identified and treatment like neck dissection and or adiotherapy/chemotherapy  
were done for the patients. 
Keywords: 
 Chest X-Rays, CT Scan, MRI Scan, PET-CT Scan, Panendoscopy, FNAC, 
HPE, Immunohistochemical Analysis. 
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INTRODUCTION 
 
 
Head and Neck cancers account for 3% of all newly discovered 
cancers metastatic carcinoma within cervical lymphnodes with an 
unknown primary tumour site accounts for 3-5% of all head and neck 
cancers, this highlights the need for proper systematic screening and 
management of  secondary’s  neck with unknown primaries. 
 
The control of such regional metastatic disease constitutes an 
important part of the process of treating head and neck cancer. The 
presence of an  enlarged node proven histologically positive for metastasis 
is  ominous findings and as a general rule it decreases the 5-year survival 
rate by at least 50%.When nodal involvement becomes multiple extends 
low in  the neck, no patient gets cured regardless of the treatment given
. 
When the primary site of carcinoma is known, focused therapy to  primary 
site and cervical lymphadenopathy can be given. Without this thorough 
knowledge clinicians are obligated to treat the entire pharyngeal axis and 
larynx to cover the possible origins of the metastatic carcinoma. The 
occult primary treatment regimen results in a significant increase in 
morbidity to the patient. 
 
 
  
2 
 
AIMS OF THE STUDY 
 
 
 
1. To analyse the histopathological type common in our population 
2. To find age and sex incidence of the malignant cervical 
 lymphadenopathy with  an unknown primary. 
3. To stage the disease at the time of presentation 
4. To interpret the possible site of primary based on the nodal 
 involvement. 
5. To describe the various investigations used to identify the primary 
 site. 
6. To discuss the ideal treatment modality for the patients. 
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REVIEW OF LITERATURE 
 
 
ANATOMY OF THE CERVICAL LYMPHATICS 
 
The lymphatics has three components; the capillaries, vessels and 
the nodes. 
Capillaries 
 
Lymphatic capillaries are tiny thin walled vessels located in the 
spaces between cells which serve to drain extra cellular fluid. Lymphatic 
capillaries are found in all tissues; each lymphatic capillary carries lymph 
into a lymphatic vessel which in turn connects to a lymphnode. Lymph is 
ultimately returned to the venous circulation. they are more abundant in 
the upper respiratory and gastrointestinal  tract 
 
Vessels 
 
Lymphatic vessels are thin walled, valved structures that carry 
lymph ,lined by endothelial cells and have a thin layer of smooth muscles, 
and adventitia that bind the vessels to the surrounding tissue, which in turn 
is enveloped by an outer connective tissue layer., with the lymph 
circulation entirely dependant on compression by surrounding muscles, 
lymphatic vessels  that carry lymph to a lymphnode is called afferent 
lymph vessel, and one that carries it from a lymphnode is called the 
efferent lymph vessel 
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Nodes 
 
A lymph node is an ovoid or kidney shaped organ of lymphatic 
system. Range in size from a few mm to about 1-2 cm long. Each 
lymphnode is surrounded by a fibrous capsule, which extends inside the 
node to form trabeculae. The substance of the node is divided into the 
outer cortex and inner medulla.. there are nearly 500 nodes in the body 
and of these 200 are in the Head and Neck. Nodes contain a subcapsular 
sinus below a prominent capsule, into which lymphatic fluid drains. This 
capsule is often the first site of metastatic growth. The fluid permeates the 
substance of the node  and exists through the hilum to enter more 
lymphatic vessels. The nodes are located between the superficial cervical 
and prevertebral fascia and thus they are very amenable to surgical 
removal. The lymphatic fluid eventually enters the venous system at the 
junction of the internal jugular and subclavian veins. 
 
All nodes are palpable when enlarged except  few retrovisceral 
nodes and those deep to the sternomastoid muscle. Because tumours have 
no primary lymphatics, cancer cells presumably gain access to the 
lymphatic system at the periphery through clefts between lymphatic 
endothelial cells. 
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Lymphatic vessels are continuously contracting; actin like filaments 
are observed in lymphatic endothelial cells.  Afferent lymphatics join a 
marginal sinus in the cortex of individual lymph nodes. When cancer cells 
lodge in lymph nodes, proliferation first occurs in the periphery and later 
in the medulla. From there anastamosing channels penetrate the body of 
the node to form hilar efferent channels into which the marginal sinuses 
drain directly. The efferent channels from a group of nodes form the  
lymphatic trunks that in turn form collecting trunks. The collecting trunks 
drain into the venous system. According to traditional view, cancer cells in 
the lymphatic system can gain access to the blood stream only through 
these terminal collecting trunks at their junctions with major blood 
vessels. 
 
LYMPHATICOVENOUS COMMUNICATIONS 
 
Many lymphaticovenous communications exist normally in body. 
Embryonically lymphatics originate from the buds of venous endothelium. 
Substances of varying sizes have been demonstrated, to pass from 
lymphatics to veins within the lymph nodes. 
 
Cells that enter the  lymphatics are transported to lymph nodes in the 
afferent vessels, and are deposited in the peripheral subcapsular sinuses of 
the node, subsequent process are variable, based on the existence of 
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lymphaticovenous anastamosis. 
 
Cancer cells may permanently lodge in the lymph nodes,or may 
traverse nodes taking egress by efferent lymphatics or through the 
lymphaticovenous communications within nodes to become 
hematogenously disseminated or may completely bypass the lymph nodes 
to enter the blood vascular system. 
 
Primary hematogenous spread may occur when cells have gain access to 
small blood vessels in the tumour stroma; such vessels develop from 
existing host vessels, presumably as a response to tumour angiogenesis. 
Blood borne tumour cells  also traverse interstitial spaces, invade the 
lymphatics and  disseminate via lymphatics. 
 
Thus in addition to the classical route from  afferent channels ,through the 
medulla to the efferent channels, cells may bypass  medulla by means of 
the marginal sinus or may enter the blood stream in the node. Additionally 
lymph nodes may be completely bypassed through collateral channels, 
although this route will be enhanced by local obstruction to lymphatic 
flow caused by metastases or reactive lymph node hyperplasia, including 
sinus histiocytosis. Tumuor cells can also bypass the nearest regional 
nodes and proceed to more remote lymph nodes. This phenomenon of skip 
metastases is seen not infrequently in head and neck cancer patients. 
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The many oppurtunities for lymphaticovenous and interlymphatic 
communication prevent any discrimination between hematogenous and 
lymphogenous metastasis anatomically. This two way communication 
may account for confused patterns   metastasis being confined to one or 
the other except perhaps in early subclinical cancer. 
  
Reversal of lymph flow can be easily produced; retrograde flow of lymph 
is enhanced and filtering efficiency of lymph nodes is decreased by 
inflammation, fibrosis from radiation and tumour growth with in them. 
Tumour emboli are able to disseminate through existing anastamoses or in 
newly formed collateral channels. 
WHY CARCINOMA FAVOUR LYMPHATIC SPREAD 
 
A first  step in the metastatic process is the detachment of cancer 
cells or group of cells from their primary tumours .Clusters have better 
chance of survival than single cells. 
 
Single cancer cells tend to enter the blood or lymphatic systems 
equally, whereas cell clumps are more restricted to enter the blood vessels. 
 
Because of intimacy with their own blood supply, sarcomas have a 
better chance than carcinomas of gaining early access to blood channels 
moreover sarcomas comparatively having lower thrombogenic activity, so 
they have less chance of being held up by intravascular thrombosis . 
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Sarcomas also preferentially separate as multicelluar units rather 
than as single cells. This would promote their survival in the blood stream 
and would tend to hinder their access to lymphatic systems. 
 
Conversely, the greater tendency of carcinomas to release single 
cells would favour early direct lymphatic spread. 
ANATOMY OF NECK NODES 
 
The nodal system of the head and neck consists of two groups  deep 
cervical chain or cervical lymphnode proper and an outlying intermediary 
group arranged into two circles, the ‘outer circle’ and the ‘inner circle’. 
The internal jugular vein which remains surrounded by nodes of the 
terminal group lies vertically between the outer and inner circles of the 
outlying group. 
 
All the lymph follows a sequential pattern of spread from superficial 
to deep and from the upper to lower parts of neck. These lower confluent 
vessels form into a jugular trunk, which on the right side ends at the 
junction of the jugular vein and the brachiocephalic vein or join the right 
lymphatic duct. On the left side the trunk will usually join the thoracic 
duct as it arches behind the lower part of the carotid sheath and in front of 
the sub clavian artery to enter the junction of the internal jugular vein with 
the brachiocephalic vein 
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Superior deep cervical group 
  
These nodes drain the soft palate, tonsil, posterior 1/3 ofl tongue, 
pyriform fossa, supraglottic larynx. The important node of this group is 
jugulodigastric node otherwise known as tonsillar or JD node. 
It liest below and behind the angle of mandible. It is enlarged in all 
of tonsillar pathologies 
Middle deep cervical group 
 
This group drains the supraglottic larynx, lower pyriform sinus and 
post cricoid area. 
Inferior deep cervical group 
 
This group drains the thyroid, trachea and cervical oesophagus. The 
important node of this group is juguloomohyoid. This lies in the 
intermediate tendon of omohyoid and receives lymph from tongue and 
submental node. 
 
Spinal accessory chain 
 
accompanies the spinal accessory nerve in the posterior triangle and 
receives lymph drainage from scalp, nape of neck and from upper 
retropharngeal nodes. 
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Left scalene node 
 
This is located at the junction of subclavian with the thoracic duct 
and receives drainage from thoracic duct. It is the important node to be 
looked for in cases of infraclavicular primaries. 
 
Supraclavicular nodes 
 
This receives afferents from spinal accessory chain and they are 
located in the posterior triangle of neck and  may be involved in case of 
infraclavicular primaries. 
 
SUPERFICIAL GROUP OF NODES 
 
This is further divided into 
 
a. inner circle of outlying group and 
 
b. outer circle of outlying group of nodes 
 
these nodes are situated around the skull base 
 
Outer circle of outlying group 
 
This forms a collar in the cervical region. 
 
Occipital nodes 
 
These nodes lie  in the apex of posterior triangle and receives 
drainage from scalp and sends  their efferent to deep cervical group. 
Post auricular group 
 
This group Lies superficially over the mastoid attachment of 
sternomastoid and  they receives afferents from post auricular area, scalp 
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and drain into upper deep cervical group. 
 
Pre auricular nodes 
 
This group lies in front of the tragus and receives drainage from 
scalp, forhead, pinna, temple, eyelid and external auditory meatus and they 
ultimately drains into deep cervical group. 
 
Parotid and facial nodes 
 
These nodes Lie within the substance of parotid gland and drains the 
orbit , parotid and infratemporal fossa. It sends   efferents to deep cervical 
group. 
Buccal nodes 
 
They Lie over the buccinator muscle near lower border of mandible. 
Drains cheek, lower eyelid, sends efferents to jugulodigastric node. 
Submental nodes 
 
This  group of nodes numbering 3-4, lies in the submental triangle 
and over mylohyoid muscle. Receives their  afferents from median plane 
structures and drains the chin and portion of lower lip, mid portion of 
gingival, floor of mouth, tip of tongue and nasal vestibule and  send 
efferent to submandibular group. 
 
Submandibular nodes 
 
Lies in the submandibular triangle over the submandibulr gland 
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itself. Facial artery is in close relation with this node. This group drains 
the centre of forehead, nose, upper lip, floor of mouth, cheek, gums, major 
part of tongue and paranasal sinuses (frontal, ethmoidal, maxillary).It 
ultimately drains into jugulo digastric and jugulo omohyoid nodes. 
 
INNER GROUP OF OUTLYING NODES 
 
This nodes lie in relation to upper aerodigestive tract and drains 
larynx, trachea and pharynx. All nodes ultimately drain into deep cervical 
group. 
 
Infra hyoid nodes 
 
Lies in relation to throhyoid membrane and drains the hypopharynx. 
 
Prelaryngeal nodes 
  
It is situated in the conus elasticus of the larynx and drains the 
larynx and superior part of isthmus of thyroid. 
Pretracheal nodes 
 
they Situated anteriorly and in close relation with inferior thyroid veins 
and drains trachea and inferior part of isthmus of thyroid. 
Paratracheal nodes 
 
Trachea and oesophagus on either side of the course of recurrent 
laryngeal nerve and drains trachea and cervical oesophagus. 
  
13 
 
Retropharyngeal nodes 
 
Consists of one median and two lateral groups. Receives drainage 
from nasopharynx, eustachian  tube and adjacent vertebra. 
CLASSIFICATION OF CERVICAL NODE GROUPS 
  
Spread patterns of cancer from various primary sites in the head and 
neck to the cervical nodes have been documented in retrospective analyses 
of large group of patients undergoing neck dissections. Since the first 
descriptions of nodal groups, various classification systems have been 
described. 
 
To address surgical management of early stage neck metastasis via 
neck dissection, various authours have proposed a number classification 
schemes. This lack of uniformity and standardization results in 
redundancy, misinterpretation and confusion among clinicians. The most 
widely accepted terminology was originally described by a group of head 
and neck surgeons at Memorial Sloan-Kettering Hospital. This 
classification uses neck levels and divides each side of the neck into 7 
separate regions 
 
 Level I submental and sub mandibular groups : the boundaries 
are - the body of the mandible, anterior belly of the contralateral 
digastric muscle and anterior and posterior bellies of the ipsilateral 
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digastric muscle two nodal subgroups are found, the submental 
group (Ia) is found in the submental triangle (anterior belly of 
digastric muscle and the hyoid bone), and the submandibular group 
(Ib) is found within the submandibular triangle (anterior and 
posterior bellies of the digastric muscle and the body of the 
mandible) 
 Level II upper jugular group: these nodes are located around the 
upper third of the internaljugular vein, extending from the skull base 
down to the carotid bifurcation inferiorly it is bounded laterally by 
the posterior border of the strenocleidomastoid muscle and medially 
by the stylohyoid muscle. Two subzones are described; nodes 
located anterior to the spinal accessory nerve are  level IIa and those 
nodes posterior to the nerve are called as  level IIb. 
 
 Level III group defines the middle jugular group nodes extending 
from carotid bifurcation superiorly down to the upper part of cricoid 
cartilage .it represents the level where omohyoid crosses the internal 
jugular vein The lateral border is formed by the posterior border of 
sternocleidomastoid muscle. The medial border is formed by the 
lateral border of the sternothyroid muscle. 
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 Level IV defines the lower jugular group and extends from the 
cricoid cartilage superiorly to the clavicle inferiorly. The lateral 
border is formed by the posterior border of sternocleidomastoid 
muscle. The medial border is formed by the lateral border of the 
sternothyroid. 
 
 Level V nodes are located along the lower half  of spinal accesory 
and transverse cervical artery .bordered anteriorly by the posterior 
border of the sternocleidomastoid muscle. Posteriorly by the anterior 
border of the trapezius and inferiorly by the clavicle. supraclavicular 
nodes are also included in this group. 
 Level VI nodes are located in the anterior compartment. otherwise 
called as visceral group. These nodes surround the middle visceral 
structures of the neck from the level of the hyoid superiorly to the 
suprasternal notch inferiorly.the lateral limit on each side is the 
anterior border  of sternocleidomastoid muscle.it contains 
parathyroid,the para tracheal pre tracheal and pre laryngeal lymph 
nodes 
 
 Level VII nodes are the paratracheal nodes inferior to the 
suprasternal notch in the upper mediastinum. 
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PREDICTABLE ROUTES OF NODAL METASTASIS FROM 
PRIMARIES 
 
Cancers of  oral cavity have a predictable manner of spread to the 
cervical nodes. Depending on  site of primary certain patterns of 
metastatic involvement are evident. 
 
Lesions of lip, anterior buccal mucosa, anterior gingival and floor of 
mouth are typically metastatic to submandibular and submental group of 
nodes. Lesions of tongue, posterior gingival, and retromolar trigone area 
involves upper deep cervical chain commonly. The submandibular node is 
the commonest node to be involved in carcinomas of floor of mouth and 
jugulodigastric is the commonest node involved in cancers of  tongue. 
 
The oropharynx consisting of retromolar trigone, anterior fauces, 
tonsil, soft plate and base of tongue drains primarily into juguodigastric 
node. The commonest node to be involved in tonsillar carcinoma was 
jugulodigastric node. Cancers of soft palate, base of tongue and 
oropharyngeal wall, because of proximity to midline tended to involve 
bilateral jugulodigastric and rarely bilateral posterior triangle nodes 
(Lindberg et al). 
  
Tumours of the nasopharnx most commonly metastasise to 
jugulodigastric nodes, bilaterally and in significant number of patients 
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posterior triangle is also involved. 
 
Tumours of the hypopharynx and supraglottic larynx tended to 
metastasise to jugulodigastric nodes followed by mid and lower deep 
cervical chains. 
 
Tumours of thyroid commonly involved upper or lower deep cervical 
group of nodes depending on site of tumour (upper pole or lower pole). 
SEQUENTIAL SPREAD 
 
Not only is the topograghic location of the involved nodes 
predictable for the various anatomic sites, but the sequential spread from 
one echelon to the other echelon is also predictable. If the first echelon of 
lymphatics is not involved,  probability of involvement of the next echelon 
is low. In lateralized lesions the probability of contralateral metastasis is 
low when the ipsilateral side of the neck is clinically negative. The 
probability increases as the extent of ipsilateral metastases increases. In 
1997 Molinari and colleagues used a statistical approach to predict the 
primary site based on the number and location of cervical  metastasis. This 
type of information is very useful in patients who present with an 
unknown primary. 
MECHANISM OF LYMPH NODE METASTASIS 
  
The current hypothesis on the development of malignancies relate to 
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alterations in the normal mechanisms of cellular proliferation and 
differentiation and a failure of cell death(apoptosis). This loss of growth 
control of genetic mutations, including the activation of proto-oncogenes 
and   inactivation of tumour suppressor genes. The resulting phenotypic 
changes provide cancer cells a growth advantage, including loss of 
response to normal growth controls, defects in response signals for 
programmed cell death, resistance to cytotoxicity, and defects in terminal 
differentiation. 
 
Proposed by Fidler, the concept of tumour heterogenicity suggests 
that tumours are composed of heterogenous subpopulations of cells 
differing in immunogenecity, invasiveness, cellular growth kinetics, 
sensitivity to cytotoxic drugs and ability to metastasize. The local tumour 
environment may favour the development of more aggressive clones in the 
formation of metastases. Although the size of individual clones with 
metastasizing potential in a given tumour is significant, only a very small 
percentage of circulating cells lead to the development of metastatic 
colonies. 
 
The events surrounding the initiation of local tumour invasion by 
epithelial tumours include a loss of cellular adhesion to surrounding 
tumour cells and basement membrane, invasion by malignant cells of the 
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subjacent connective tissue by the production of cellular enzymes and 
growth mediators, cellular attachment to extracellular membrane 
molecules, neovascularisation and entry or exit from the circulation 
through the attachment to endothelial cell ligands. A repeat of this events 
occurs at the metastatic sites. 
 
In case of squamous cell carcinoma of the head and neck, malignant 
cells may progress from carcinoma in situ to microinvasive carcinoma, to 
a deeply invasive tumour with lymphatic metastasis. Interestingly a head 
and neck squamous cell carcinoma has the ability to manifest at both 
extremes of histopathological development in the same anatomic location. 
The critical step in the transition from carcinoma in situ to microinvasive 
carcinoma is the destruction of the basement membrane. This destruction 
is accomplished by production of specific proteolytic molecules by the 
tumour cells, including matrix metalloproteinases, collagenases and 
plasminogen activators. 
 
Angiogenesis is the growth of new capillaries by sprouting from 
established vessels. In normal tissues, self-limiting angiogenesis is a part 
of reproduction and organogenesis in addition to wound repair and 
healing. Conversely, pathological angiogenesis is not auto regulated, but 
results from alterations in growth control mechanisms of disease process. 
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Various tumour derived factors (eg, prostaglandin E2,platlet-derived 
growth factor, transforming growth factor-beta, transforming growth 
factor-alpha, beta-fibroblast growth factor) are still being investigated for 
their propensity to facilitate endothelial cell proliferation. 
 
Recent research looking specifically at the production of cytokines 
regulating immune, inflammatory and angiogenetic response in patients 
with laryngeal squamous cell cancer has revealed higher serum 
concentrations of the cytokines, interleukin-6, interleukin-8 and vascular 
endothelial growth factor. These agents may be important in 
proinflammatory and proangiogenetic responses of tumour cells. 
 
The ability of a tumour to stimulate an angiogenic response should 
directly determine the capability of a tumour to metastasize and ultimately 
kill the host. The literature notes conflicting reports regarding microvessel 
density and nodal metastasis in head and neck squamous cell carcinomas. 
Tumour sites of varying origins with different vascularisation patterns at 
their primary sites may behave differently. Malignancies of  head and neck 
especially head and neck squamous cell carcinomas are the result of a 
series of genetic misadventures of squamous epithelial cells leading to 
malignant transformation. Variable genetic susceptibility, prolonged 
tobacco and alcohol exposure, viruses and immune suppression all can 
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facilitate these genetic derangements. 
Tumours invade local connective tissue by the production of 
proteinases and the expression of surface markers that facilitate 
attachment to extracellular matrix components. Tumor growth and size 
being limited by available nutrients from the surrounding milieu, 
recruitment of host capillaries leads to the formation of an intramural 
blood supply. Capillary lymphatic invasion by tumour cells allow 
malignant cell dissemination and the establishment of histologically 
identical tumours at distant sites. 
 
Most recently, the expression of vascular endothelial factor-D in a 
mouse tumour model was found to lead to the lymphatic spread of tumour 
cells, tumour angiogenesis and tumour growth. 
 
The dissemination of tumour cells beyond the primary site 
unfortunately remains the most significant factor in prognosis. 
LYMPH NODE AND TUMOUR IMMUNITY 
 
An early event in  metastatic process is the detachment of cancer 
cells from the parent tumour. Because a tumour has no primary 
lymphatics, cancer cells presumably gain access to the lymphatic system 
through the clefts between the lymphatic endothelial cells at the invasive 
tumour periphery. Once inside the lymphatic channels, cells are carried by 
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the afferent lymphatics to the regional nodes where they lodge and 
proliferate. 
 
The permeation theory of metastasis introduced by Handley in 1907 
was based on autopsy studies of patients who had died of breast cancer 
and melanoma. He concluded that lymphatic metastasis originated by 
continuous permeation of lymphatics radiating away from the primary 
tumour site. The permeation concept of lymphatic metastasis was the basis 
for the development of in continuity (en bloc) dissection of nodes with 
primary cancer for head and neck. 
 
Von Recklinghuasen noticed that metastasis could be found in the 
lymph glands when tumour did not involve the intervening lymphatics, 
and the embolic spread of metastasis is now generally accepted. 
 
Handley’s concept of permeation still applies to some clinical 
situations; generally recurrent cancer with obstruction of the normal 
lymphatic pathways leading to retrograde spread and tumors in certain 
sites such as large floor of mouth tumours with direct extension to the 
submandibular area. Previously untreated primaries even if massive 
seldom involve the neck by direct extension. 
 
In the past it was believed that regional lymph nodes behave as traps 
against tumour cell dissemination. This ‘Filter Barrier’ hypothesis 
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proposes that regional lymph nodes serve as mechanical and biologic 
filters in which phagocytosis assists the more mechanical phase of 
particulate trapping. In various studies, it has been shown that cancer cells 
can traverse nodes that themselves are free of tumour, implying that the 
node is an ineffective barrier. 
 
Fischer and Fischer reported that nodes were able to trap 90%of 
infused red blood cells and 40% of carcinoma cells. The nodes did not 
become saturated. Some studies have shown that nodes are potential 
barriers to infused tumour cells for only a limited time-approximately 3 
weeks. Thereafter the tumour cells are no longer effectively retained. 
 
In a study it has been shown that as the primary tumour increased in 
size the number of cells in the nodes remained constant. The authors 
concluded that the nodes had a reasonably constant holding capacity and 
that above such a threshold, all other tumour cells passed on into efferent 
channels and the general circulation. 
 
Although the role of regional lymph nodes as a barrier to cancer 
spread and as a possible site of antitumour immune response is putative 
and remains to be established, majority of the workers are of the opinion 
that some sort of dynamic interaction does occur when tumour. 
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Emboli encounter lymphocytes within the nodes of head and neck 
cancer patients. The regional nodes are felt to be important for the 
initiation of systemic immunity to cancer cells, especially to weekly 
antigenic tumours. Patients who do not become positive for nodes at any 
time are thought to have immune competence that is entirely able to 
eliminate disseminated tumour cells in the nodes and elsewhere  
throughout the body. Conversely the positive lymph node may denote 
either a failure of the above mechanism, or a change in the biologic nature 
of the tumour cells, or that the number of disseminated tumour cells have 
exceeded the capacity of the node for cell destruction. 
 
The existence of an enlarged node does not necessary indicate the 
presence of metastatic spread, especially if the node is soft. In this case it 
may represent no more than a coincidental infection or the mounting of an 
immunological reaction within the node. 
 
However just as this is true, it has been estimated that a node smaller 
than 1 cm is impalpable and yet may contain 10
6
 – 107 tumour cells. The 
principal problem for the clinician is how to decide whether a node which 
is palpably enlarged is involved with metastasis or not. At present such a 
decision remains purely clinical. Some authors have recommended that 
any enlarged palpable node in the drainage area of a histologicaly proven 
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primary should be considered as metastatic until otherwise proved. 
Lindberg (1972) defined a clinically positive node as one which is greater 
than 1cm in size, spherical rather than a flat ovoid in shape and harder in 
consistency than a non metastatic node. 
 
Throughout this study the above criteria of Lindberg was used to 
differentiate a metastatic from a non metastatic node. 
THEORIES FOR THE OCCULT PRIMARY 
 
It has been hypothesized earlier that the patient with malignant 
cervical lymphadenopathy but unknown primary site may in fact have no 
upper aerodigestive tract primary site. Rather the tumor primary developed 
in the neck within squamous cells remaining as remnants of brachial cleft 
cysts. Although this theory is intriguing, little evidence has been presented 
to support it and it has largely fallen out of favour. 
 
The other theory is that these patients have exhibited spontaneous 
regression of the primary tumor site with persistence of cervical 
metastasis. 
Unfortunately there is no evidence for the spontaneous regression of 
squamous cell carcinoma. 
 
Current theory is that unknown primary tumours are likely to be, 
primary tumours that exist in the upper aerodigestive tracts or skin, but 
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subclinical at the time of presentation. Thus unknown primary tumours 
remain undetected but are presumed to be present. Anecdotal support of 
this theory includes the identification of some of the primary tumours 
during or after treatment. 
 
HISTOLOGICAL GRADE OF THE TUMOUR AND ITS 
INFLUENCE 
 
Histologically a squamuos cell carcinoma consists of an admixture 
of normal squamous cells and atypical anaplastic squamous cells. The 
more malignant the tumour, the greater is the number of atypical cells. The 
a typicality expresses itself in terms of variation in the size and shape of 
cells, hyperplasia and hyperchromatasia of the nuclei, absence of 
intercellular bridges, atypical mitotic figures, and keratinisation of cells. 
 
Differentiation in a squamous cell carcinoma takes place in the 
direction of keratinisation, and so the degree of keratinisation represents 
the essential feature in the system of histological grading introduced by 
Broder (1921).This grading system recognizes four grades of severity 
according to the proportions of differentiated cells present in the tumour. 
 
 Grade I - more than 75% of the cells are differentiated 
 
 Grade II – between 50% to 75% of the cells are differentiated 
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 Grade III – between 25% to 50% of the cells are differentiated 
 
 Grade IV – less than 25% of the cells are differentiated. 
 
 
Alternatively squamous cell carcinoma can be graded as 
 
1. Well differentiated – tumours with minimal pleomorphism, few 
mitoses, large number of horn pearls and abundant keratinisation. 
 
2. Moderately differentiated – tumours where typical cells are 
conspicuous, few horn pearls are present and keratinisation is much 
less evident. 
 
3. Poorly differentiated – tumours with much cellular and nuclear 
pleomorphism, negligible keratinisation and absence of horn pearls. 
The relevance of histologic grade of tumour to prognosis is well 
established. Arthur and Farr (1972) studied the prognostic significance of 
histologic grade in squamous cell carcinoma of oral cavity and oropharynx 
and demonstrated a clear relationship between the histologic grade and 
metastatic nodal disease, stage of the disease and cure rate. They noted a 
proportionate increase in nodal involvement with increasing histologic 
grade of the tumour and suggested that histologic assessment should play 
a part in designing the therapeutic approach.Other authors have also 
appreciated the usefulness of histologic grading as a clue to overall 
prognosis. 
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TNM STAGING 
 
The current classification was proposed by the American Joint 
Committee for Cancer Staging and end results reporting in 2017 and is 
being widely adopted. 
 
In this classification, the recommended tumour (T) designation 
varies from one anatomic region of the head and neck to another, but the 
node (N) and distant metastasis (M) categories is applicable to all of the 
areas of the head and neck. Stage grouping based on the TNM stage is also 
similar throughout the head and neck. 
 
The (N) and the (M) categories as well as the stage grouping, which are 
constant for all the head and neck regions are discussed first. 
N –Classification of all head and neck cancers (AJCC, 2017)
1
 
 
 Nx - nodes cannot be assessed. 
 
 N0 - no clinical positive nodes. 
 
 N1 – single clinically positive ipsilateral node  3cm or smaller in 
greatest dimension and ENE- 
 
 N2 –Metastasis in a single ipsi lateral node  larger than 3cm  but not 
larger than 6cm in greatest dimension  or 
 multiple  ipsilateral nodes none over 6 cms in greatest dimension 
and ENE- 
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 or in bilateral or contralateral lymphnodes none larger than 6cm in 
greatest dimension. ENE- 
 
N   2a – single  Ipsiolateral node larger than 3cm but not larger than 6cm 
in greatest dimension and ENE-. 
 
N 2b – multiple ipsilateral node none over 6cms. 
N2c - metastasis in biateral or contralateral lymphnodes none larger than 
6cm in greatest dimension and ENE- 
 
 N 3  –metastasis in a lymphnode larger than 6cm  in greatest 
dimension and ENE- 
 or  metstasis in any node(s) with clinically overt ENE+. 
 
1. N3a –metastasis in a node larger than 6cms in greatest dimension 
and ENE- 
 
2. N3b –metastasis in any node(s) with clinically overt ENE+ 
 
NOTES: 
 
1. Midline nodes are considered ipsilateral nodes 
 
2. ENE is defined as invasion of skin, infiltration of musculature, 
dense tethering or fixation to adjacent structures, or cranial nerve, 
brachial plexus, sympathetic trunk or phrenic nerve invasion with 
dysfunction 
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M - Classification of all head and neck cancers (AJCC,2017) 
 
 Mx – metastasis not assessed 
 
 M0 – No known metastasis 
 
 M1 – Distant metastasis present 
 
 
STAGE GROUPING OF HEAD AND NECK CANCERS (AJCC, 
2017) 
 
Stage I – T1, N0, M0 
 
Stage II – T2, N0, M0 
 
Stage III - T3, N0, M0 
 
T1,2,3, N1, M0 
 
Stage IVa – T4, N0,1, M0 
 
T1-4, N2, M0 
 
IVb - Any T, N3, M0 
 
T4b, Any N, M0 
 
IVc – Any T, Any N, M1 
 
 
The T – Classification of the Oral Cavity and Oropharyngeal Tumour 
is Described Below (AJCC, 2017) 
 Tx –  primary tumour cannot be assessed 
 
 T0 – No evidence of primary tumour 
 
 Tis – Carcinoma in situ 
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 T1 – Tumour </=2cm,</=5mmdepth of invasion 
 
 33 
 
 T2 – Tumour </=2cm,depth of invasion >5mm and </=10mm or 
 
 tumour  >2cm but </= 4cm and </=10mm depth of invasion 
 
 T3 – Tumour more than 4 cms in greatest diameter  or any tumour 
 
 >10mm depth of invasion 
 
 T4  – Tumour more than 4 cms with invasion into contiguous 
 
 structures such as floor of mouth,  skin, muscles and bone. 
 
 T4a –moderately advanced local disease 
 Tumour involving cortical bone, deep tongue musculature, maxillary 
sinus, skin of face 
 
 T4b –very advanced local disease 
 Tumour involving maxillary plates, pterygoid plates, skull 
base,encases the internal carotid artery. 
 
RISK FACTORS FOR HEAD NECK CANCER 
 
It has been estimated that  use of tobacco and alcohol  account for 
up to 80 percent of cases of head and neck squamous cell carcinoma. Both 
act throughout  aerodigestive tract, contributing to the field cancerisation 
effect,  both can induce genetic alterations, such as mutations in the p53  
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tumour suppressor gene. Other factors which may play a role include viral 
infection, occupational exposure,. radiation, dietary factors and genetic 
susceptibility. 
 Tobacco-there is an increased risk of head and neck squamous cell 
carcinoma from a 5-to-25 fold, in heavy smokers compared to 
 nonsmokers. The relative risk in current tobacco users is 6.5.the 
relative risk increased with the duration of smoking and gradually 
declined after smoking cessation 
 .The age at onset (below 18 years of age) and duration of smoking 
(over 35 years) were high risk factors. Passive smoke exposure also 
a contributing factor. 
 
 ·Epidemiologic studies have suggested that cigar smoking is 
associated with  increased incidence of head and neck squamous cell 
carcinoma and smokeless tobacco with increased risk of cancer of 
the tongue, oral cavity and pharynx. Marijuana use may modestly 
increase the risk of cancer, an effect that is magnified by cigarette 
smoking. 
 Alcohol –although it is  difficult to separate the effects of smoking 
and alcohol, studieshave consistently shown that alcohol 
consumption increases risk of cancer in the upper aerodigestive 
tract. relative risk of developing cancer appears to be dose 
dependent, ranging from 5.5(alcohol intake greater than 50g/day) to 
33.8(alcohol intake greater than 120g/day) .Drinking liquor 
associated with greater risk than drinking only wine. Moderate 
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alcohol intake (10 to 19g/day) has no effect among nonsmokers. 
The combined effect of alcohol and smoking, with the risk of 
developing Head and Neck cancer being as much as 200 times greater for 
heavy smokers and drinkers 
 
 Epstein-Barr virus-The strongest association between a virus and 
head and neck cancer is the  Epstein-Barr virus and nasopharyngeal 
carcinoma. EBV is the causative agent for oral hairy leukoplakia 
also 
 
 Human papilloma virus- HPV type-16 has been detected in 8 to 
36% of head and neck cancer. It contribute by direct effects on 
proliferation and by increasing mutational frequency in the host 
cells. The prevalence of HPV infection appears to be site specific, 
and highest in invasive tumours of the oropharynx and oral cavity. 
The presence of HPV appears to confer a better prognosis. 
 
 Occupational exposure – These include asbestos,, pesticide, 
polycyclic aromatic hydrocarbons, textile workers, wood workers, 
manufacturers of mustard gas,, plastic and rubber products, 
naphthalene refineries, ethanol, sulfuric acid mist, leather and paint 
workers, automobile mechanics, construction workers (cement), 
metal workers and bartenders (passive smoking). Formaldehyde was 
classified as a carcinogen in 2004 because of  association with 
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nasopharyngeal carcinoma and possibly cancers of the nasal cavity 
and paranasal sinuses. 
 Radiation – Prior radiation for either malignant or benign disease  
linked to head and neck cancer. 
 
 Diet – Risk of nasopharyngeal carcinoma is increased in frequent 
consumers of preserved meats which contains high levels of added 
 nitrites. Increased risk of head and neck squamous cell carcinoma 
has  been associated with  frequent intake of eggs and red meat and 
a low carotenoid intake. 
 
 Genetic factors – First degree relatives and siblings of patients with 
head and neck squamous cell carcinoma are  likely to develop upper 
aerodigestive tract cancer . 
 Others –. Lip cancer is seen in renal transplant recipient. 
MELANOMA OF UNKNOWN PRIMARY 
Primary   melanoma of the head and neck represents approximately 
25% to 30% of all melanoma. Rarely, melanoma is identified in cervical or 
parotid lymph nodes without evidence of a primary tumor. Many authors 
theorize  that metastatic melanoma in the cervical lymph node  represents 
metastases from a primary tumor that has undergone spontaneous 
regression. 
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In working up a patient with metastatic melanoma of unknown 
origin, it is important to obtain a detailed history of any previous skin 
lesions that disappeared or were removed. Pathology slides  of  all  
previously excised “benign skin lesions” must be reviewed by an 
experienced dermatopathologist. As with all newonset neckmasses, an 
FNA is often  the initial step that leads to a diagnosis of melanoma. 
Melanoma - specific immune histologicstaining, such as MART-1 
(melanoma antigen recognized by T cells), HMB-45, or S-100, may help 
to confirm the histologic diagnosis. Once the histology is confirmed the, 
the practitioner should search for an occult melanoma primary lesion. This 
evaluation should include once  complete dermatologic skin examination 
and a search for the rare occuitl visceral  melanoma of the conjunctiva, 
mucosa of the head and neck, or gastrointestinaltract. If the thorough 
work-up fails to identify the  primary occult melanoma, the treatment plan 
must focus on the cervical disease and the possibility of distant  metastatic 
disease. The role of whole-body PET imaging in melanoma is under 
debate. In the initial evaluation of  early stage cutaneous  melanoma, PET 
imaging has not prove deficient. A recent study prospectively evaluated 
the impact of PET imaging on the detection of occult lymph node  
metastases and distant metastases PET scan sensitivity was 21%, and 
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specificity was 97% in detecting occult metastatic disease in patients with 
early-stage melanoma. Other researchers have suggested that PET imaging 
may be a valuable adjunct in staging patients with recurrent melanoma or 
more advanced tumors. Metastatic melanoma to cervical lymphnodes in 
the absence of a known primary origin remains a disease to be treated 
surgically. Patients presenting with jugularchain involvement require a 
modified radical neck dissection (levels I–V), sparing all vital structures  
not involved with  disease. The surgeon must consider a posterior-lateral  
neck dissection for treatment of  metastatic melanoma in  level V,  the  
postauricular, and the occipital nodal basins. Interferon alfa 2-b remains 
the only adjuvant therapy for melanoma  approved  by the US  Food  and 
Drug Administration.  All  patients  with  cervical  metastasis  (N1 disease  
or  greater)  are  candidates.  In addition,  patients with  regional  (stage  
III) disease  in  the  setting  of  multiple positive lymph nodes or ECS have  
gained increased locoregional  control  with  the  administration  of  
postoperative hypofractionated  radiotherapy (30 Gy in  five fractions). 
Alternative systemic treatment including gene therapy and  
biochemotherapy,  are  available  within the context. 
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Cystic metastatic disease in  the neck 
A  cystic  quality  to  metastatic  cervical  carcinoma  of  unknown 
primary  origin  should  raise  suspicion  for  papillary  carcinoma  of  the  
thyroid  gland,  tonsillar  SCC,  and branchial cleft carcinoma. Branchial 
cleft  carcinoma represents a primary carcinoma arisin from a congenital 
branchial cleft remnant and continues to be  controversial. Primary occult 
SCC arising from Waldeyer’s  ring can  generate  cystic  metastatic  
disease  in  up  to  50%  of patients. Therefore,  strict  criteria for branchial 
cleft carcinoma are required. The criteria  for diagnosis of branchial cleft 
carcinoma include 1)  location of the tumor along the anterior border of 
the sternocleidomastoid muscle, which represents  the traditional course  
of a branchial cleft cyst; 2) histologic  findings  consistent  with  the  
presence  of  a  branchial cleft cyst; 3)  histologic findings  consistent with  
the carcinoma  arising  within  the  branchial  cleft  cyst  wall;  and 4)  no 
evidence  of a primary SCC in  the upper aero digestive tract for a 
minimum 5-year  follow-up period. Given these strict criteria, the  
clinician  cannot  confirm  branchial cleft carcinoma until 5 or more years  
of follow-up without identification of an  occult primary site  elsewhere. 
As a general rule, any adult with a cystic neck mass resembling a 
branchial cleft cyst warrants a thorough work-up, including imaging and 
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FNA biopsy to rule out malignancy. A recent report  from the University  
of Pittsburgh describes  40  adult  patients  presenting  with  cystic  neck 
masses. PET imaging fared no better than  traditional CT scan  in  the  
identification  of  malignancy  in  these  patients. The  authors  concluded  
that  a  thorough  clinical  evaluation by  an  experienced  head  and  neck  
surgeon,  in  conjunction with  contrast - enhanced CT  and FNA biopsy, 
is  sufficient to evaluate  patients  with  a cystic cervical neck mass 
DIAGNOSTIC EVALUATION 
 
A complete and detailed history of the present and past illness with a 
thorough physical examination is  mandatory to the workup of the patient. 
 
Laboratory studies are not typically used in the workup of a patient 
but are used to evaluate a patient’s anaesthetic risk and to provide baseline 
laboratory data. 
 
Serology of Ebstein-Barr virus has been shown to correlate with the 
presence of nasopharyngeal carcinoma. 
 
Chest radiograph 
 
Chest radiograph is taken for all patients. If any suspicious lesion 
found in chest radiograph then CT scan is indicated. If a lung cancer is 
found then it is evaluated separately. 
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CT scan 
 
The neck CT scan is important in the search for an occult primary 
site and also to evaluate the extent of nodal diseases, and to check for 
obvious extra capsular spread and examine for suspicious nodes in the 
contralateral neck. Contrast enhanced CT from the base of the skull to the 
level of the thoracic inlet is indicated. CT can identify tumours of the head 
and neck based on either anatomic distortion or specific tumour 
enhancement. In general tumours enhance more than any normal head and 
neck structures except mucosa, extraocular muscles, and blood vessels. A 
radiologically heterogenous appearance or the presence of central low 
attenuation may indicate pathologic lymphadenopathy, even in small 
lymph nodes. 
 
MRI scan 
 
MRI has multiplanar capabilities, it provides superior soft tissue 
contrast and it identify early evidence of dural involvement or perineural 
invasion .so It is  useful for assessment of local spread of nasopharyngeal 
carcinoma and sinonasal carcinoma. MR Angiography will generate 
images of large arteries and veins noninvasively without the use of IV 
contrast. This is reserved for cases where tumour is thought to encase a 
major vessel. 
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PET scan 
 
PET  has high sensitivity, specificity and accuracy for the detection 
of unknown primary  tumours with cervical lymphnode metastasis.. 
Potential clinical applications for the PET scanning include improved 
pretreatment staging, identification of occult primary site, estimation of 
treatment response and differentiation of early recurrence from scar tissue. 
Many incorporate this imaging modality in their diagnostic evaluation for 
an occult primary tumour. Tumour cells having  higher metabolic rate than 
normal tissue; head and neck neoplasms have an increased glycolytic rate 
and  Thus head and neck neoplasms are good candidates for metabolic 
imaging and can be traced using a glucose analog, 2-[fluorine-18]fluoro-
2deoxy-D-glucose. (FDG). 
 
FDG uptake reflects cellular metabolism and cellular processes such 
as infection., neoplasm or inflammation. They are characterized by 
increased metabolic activity and consequent accumulation of the FDG 
tracer. This accumulation which appears as hot spots on PET imaging may 
help to localise an unknown primary tumour. 
 
The Danish study demonstrated that FDG PET detected a primary 
tumour in 24% of patients with metastatic cervical adenopathy and 
otherwise negative clinical and radiological evaluation. 
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The key limitation of PET has been the size of tumour it can detect. 
New PET have resolution of 5mm.and tumours of the supraglottic region 
and waldeyer's tonsillar ring are the most difficult to be diagnosed with 
FDG-PET. An additional limitation of PET scanning has been the 
anatomically nonspecific image produced by these scanners. Hot spots 
appear as general regions without good borders.  whereas it may be 
possible to state for eg; that left side of the base of the tongue appears 
‘hot’, so any additional information regarding the size or localization 
would be inaccurate. 
 
Newer scanners that supplement PET with CT fusion techniques are 
becoming available. These machines can overlay the images so that the 
hot areas are visible as coloured halos over the CT scan image, and thus 
greatly facilitating the accuracy and localization of the PET technology. 
Panendoscopy of the upper aerodigestive tract with biopsy samples 
obtained from suspicious areas should be done. 
Mucosal biopsies from nasopharynx, fossa of rosenmuller, tonsils, 
pyriform sinus, hypopharynx, vallecula, postcricoid region and base of 
tongue should be done routinely for all patients with unknown primary. 
 
Previous studies have suggested that the most common sites of 
primary tumour detected on panendoscopy were the nasopharynx and 
42 
 
hypopharynx. In a recent University of Florida study, the most common 
sites of primary cancer detected seen now to have shifted to include the 
tonsillar fossa or the base of the tongue. 
 
Because the tonsil remains a common site of primary tumour, most 
clinicians advocate tonsillectomy in addition to directed biopsies in the 
workup of an unknown primary tumour. Questions regarding whether 
random tonsil biopsies or tonsillectomy should be performed in the 
evaluation of an unknown primary site and whether such tonsillectomy 
should be ipsilateral or bilateral tonsillectomy continue to be controversial. 
 
In a 1998 study at john Hopkins hospital McQuone et al 
demonstrated that the detection rate of occult tonsillar carcinoma is 
increased by performing tonsillectomy rather than focal tonsillar biopsy. 
Although only 13% of tonsillar biopsy specimens were positive for 
squamous cell carcinoma, 39% of the patients undergoing bilateral 
tonsillectomy for workup of unknown primary site was found to have 
squamous cell carcinoma within tonsil. Furthermore one patient was found 
to have squamous cell carcinoma in both tonsils, strengthening the 
argument for bilateral tonsillectomy. Bilateral tonsillectomy does not 
significantly increases the morbidity associated with unilateral 
tonsillectomy and eliminates the asymmetry that can confound follow up 
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examination after a unilateral procedure. 
Other Diagnostic Procedures; 
Recently promising results have been reported with LASER 
INDUCED FLUORESCENCE IMAGING performed in parallel to pan 
endoscopy. Another diagnostic method to identify the site of origin with 
higher sensibility is FDG-SPECT, however its usefulness is still debated 
MOLECULAR ASSAYS: 
Some molecular assays have recently been proposed to differentiate 
the potential primary site. Detection of EBV with the use of insitu 
hybridization in metastatic lymphnodes may suggest nasopharyngeal 
tumour Human Papilloma virus HPV detected by polymerase chain 
reaction mayindicate oropharyngeal cancer. 
Microsatellite Mutation Analysis of metastatc nodal tissue and 
samples of normal pharyngeal mucosa was also proposed. 
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Immunohistochemical Analysis for Cervical Lymph Node Metastasis 
of unknown Primary Origin 
Stain/histologic feature Suggested primary site/neoplasm 
Thyroglobulin Thyroid carcinoma 
Calcitonin Medullary carcinoma of thyroid 
PSA/prostatic acid phosphatase Prostate 
Alpha feto protein Liver, stomach, germ cell 
CEA Pancreas, breast, ovary 
Estrogen/progesterone receptor Breast 
Psammoma  bodies Ovary, papillary thyroid carcinoma 
Signet ring cells stomach 
Cytokeratin Squamous cell carcinoma 
Epithelial membrane antigen Squamous cell carcinoma 
MART-1 Melanoma 
HMB-45 Melanoma 
S-100 Melanoma 
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TREATMENT 
 
Several different treatment strategies are available for  management 
of the  unknown primary site and squamous cell carcinoma metastatic to 
the neck. 
Whether radiotherapy  is sufficient treatment for control of neck 
disease and whether potential primary sites should be irradiated or simply 
followed are controversial. 
Additional controversy is on whether radiation should be offered to 
patients pre-or postoperatively. Finally, questions have surfaced about 
whether the contralateral neck needs to be treated. Which treatment 
strategy provides best outcome remains a subject of debate in the 
literature. 
 
In discussing treatment strategies, it is important first to have an 
understanding of prognostic factors. In all large series, lymph nodal stage 
has correlated with outcome. Supraclavicular lymph node metastases are 
more likely to be associated with disease below the clavicles, and hence, 
are associated with poorer survival. Histologic extracapsular spread has 
been noted to affect survival adversely in most large series as well. As 
might be expected, more primary sites were identified in patients treated 
with surgery than in patients treated with radiatiotherapy. Although 
treatment protocols may vary by institution and clinical bias, there is 
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consensus that advanced nodal disease and extracapsular spread 
necessitate more aggressive therapy. 
 
For a few patients presenting with N1 or N2a disease, single modality 
therapy is a reasonable approach. Acceptable courses of treatment include 
neck dissection alone, radiation alone, and neck dissection plus radiation if 
extracapsular spread is noted on histopathologic analysis. A 1998 review 
from M.D. Anderson recommends that patients with N1 or small mobile 
N2a disease be treated with neck dissection alone and that postoperative 
radiation therapy be reserved for cases of extracapsular spread, multiple 
nodes or connective tissue invasion. The 5-year disease free survival rates 
were 85% in patients with a solitary node and 58% for patients with 
multiple nodes. Similarly, in patients who have undergone an excisional 
biopsy of a solitary node, the neck may be treated with radiation alone 
with a 95% likelihood of neck control. Thus single modality treatment in 
patients with N1 or N2a disease is reasonable .For patients with disease 
beyond N1 or N2a combined modality therapy is recommended. 
 
Patients with more advanced disease, in contrast are triaged into an arm of 
treatment that includes both surgery and radiotherapy. The timing of 
radiotherapy is also a source of controversy. Proponents of preoperative 
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radiation therapy argue that surgical complications delay the initiation of 
radiation therapy, target tissues are theoretically better oxygenated in the 
preoperative state, and radioresistant primary tumours may become 
evident over the course of radiation therapy and can be removed with one 
definitive surgical procedure if radiation therapy is implemented before 
the planned neck dissection. 
 
Proponents of postoperative radiation therapy argue that a neck 
dissection before radiotherapy allows improved delineation of disease 
extent and better staging through pathologic evaluation of the neck 
dissection specimen. Although adjuvant chemotherapy has shown mixed 
results, it is often recommended in cases of inoperable disease, or with 
distant metastases. There is some evidence that concurrent chemotherapy 
and radiotherapy in the postoperative setting improve locoregional control 
rates. 
 
The decision to include suspected primary sites in the radiation field 
also remains controversial. Certainly the challenge facing the clinicians is 
deciding how to maximize the chance of survival while minimizing the 
treatment morbidity. Review of the literature reveals a trend toward 
treating both the ipsilateral and contralateral necks as well as potential 
mucosal primary sites. Certainly many of the primary sites (base of 
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tongue, nasopharynx, supraglottis) are known for their bilateral nodal 
drainage. Tong et al point out that treatment limited to the involved side of 
the neck alone may compromise further radiation therapy should a primary 
mucosal site emerge. For this reason, bilateral radiation to the neck and 
mucosal sites is recommended. 
 
Debate continues to center around which portals should be included 
in the radiation therapy. The consensus seems to be that the oral cavity and 
a laryngeal strip can be excluded, but the base of the tongue, hypopharynx, 
and supraglottic sites should be included. The decision to include the 
nasopharynx should be based on whether metastases are high and posterior 
and whether demographic factors suggest that the patient is at high risk for 
a nasopharyngeal primary site. Sparing the oral cavity and of an anterior 
strip approximating the anterior true vocal cords may significantly 
decrease the morbidity of the mucosal irradiation. 
 
Reddy et al also reported a series comparing ipsilateral radiotherapy 
with radiation delivered to both sides of the neck and sites of mucosal 
primaries. Significantly better neck control was demonstrated in the group 
receiving radiation to both sides of the neck and mucosal sites. 
 
Finally, recent discussion has focused on the extent of neck 
dissection indicated in the patient with a cervical metastasis and unknown 
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primary lesion. A growing body of evidence suggest that a selective neck 
dissection including the involved level and contiguous levels with 
appropriate sacrifice of the involved structures is reasonable. Appropriate 
use of selective neck dissection can minimize the postoperative morbidity 
associated with modified and radical neck dissection without 
compromising neck control and survival. 
Even with advances in treatment protocols, the overall survival for 
squamous cell carcinoma metastatic to a cervical node with an unknown 
primary site remains approximately 50%.The 2-,5- and 10 year disease 
specific survival rates have been reported to be 82%,74% and 68% 
respectively. Nodal stage has been shown to be significantly associated 
with disease specific survival. 
 
CHEMOTHERAPY 
 
The role of chemotherapy in head and neck cancer is expanding and 
its utility varies with the stage of the disease. For patients with metastatic 
or incurable locoregional disease chemotherapy is palliative. In contrast 
for patients with potentially curable locoregional head and neck cancer, 
chemotherapy is an integral part of multimodality approach. In such cases 
chemotherapy may be administered as induction therapy, concomitant 
with radiotherapy or with a combined approach. 
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Single agent chemotherapy 
 
Several cytotoxic chemotherapy drugs have significant activity in 
advanced head and neck cancer when administered as a single agent. 
Direct comparisons of efficacy are limited by the paucity of randomized 
trials, and this complicates the establishment of recommendations for 
standard of cure. Although most patients will be treated with combination 
chemotherapy, occasionally single agents may be used for palliation. 
 
The choice of agents depends in part upon the patient’s clinical 
status and the ability to tolerate drug-specific side effects. Acceptable 
drugs include paclitaxel, docetaxel, methotrexate, cisplatin, carboplatin, 
ifosfamide and 5-Fluorouracil. 
 
In advanced squamous cell head and neck cancer, the taxanes have 
emerged as perhaps the most active of all single agents. 
General principles of combination chemotherapy 
 
Many combination chemotherapy regimens have been studied for 
the treatment of advanced head and neck cancer. Prior to mid 1980s, the 
most aggressive regimens included methotrexate and generally consisted 
of combinations of two or four drugs, often methotrexate plus cisplatin, 
bleomycin, 5-FU or vincristine. These regimens have been largely 
replaced by three categories of drug combination: 
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 The combination of a platinum analog (cisplatin or carboplatin) and 
5-FU. 
 
 The combination of a platinum analog and a taxane (paclitaxel or 
docetaxel). 
 
 The combination of a taxane, a platinum analog and 5-FU with or 
without leucovorin. 
Recommendations for combination chemotherapy for advanced 
head and neck cancer. For metastatic or recurrent disease, any of the 
several regimens may be used. Since none has been proven yet to prolong 
survival, care must be exercised to avoid major acute or chronic toxicities 
and consideration should be given to single agent therapy. For patients 
with good performance status, appropriate combinations include cisplatin 
or carboplatin plus 5-FU, or platinum analog plus a taxane. 
NEW THERAPIES 
 
Monoclonal antibodies 
 
Cetuximab- The majority of head and neck cancers over express 
endothelial growth factor, making them a good target for cetuximab, an 
anti-EGFR monoclonal antibody that inhibits receptor activity by blocking 
the ligand binding site. In addition to being investigated as a single agent 
and in combination with cytotoxic chemotherapy, cetuximab is also given 
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as a radiosensitiser. 
 
Other potential agents that block the activation of EGFR are the 
tyrosine inhibitors such as geftinib and erlotinib. 
Gene therapy 
 
Gene therapy utilize a vector to deliver genetic material to a cell in 
an attempt to alter its biology via expression of the delivered gene. The 
majority of  the effort has been aimed at modification of p53.The p53 gene 
is inactivated in approximately one half of squamous cell head and neck 
cancers. 
 
ONYX-015 – It is an adenovirus containing a deleted E1B 55-kDa 
gene, which actively replicates in, and lyses p53-deficient cells. 
 
RPR/INGN 201 – It utilizes a replication deficient adenovirus to 
deliver a cytomegalovirus promoter and a wild type p53 gene. 
 
Cisplatin/epinephrine injectable gel – for patients with refractory or 
multiple recurrent local tumour involvement, a novel strategy is direct 
application of cisplatin into the tumour itself. 
RADIOTHERAPY 
 
Radiation may be given as a once daily treatment or hyper 
fractionated (twice daily).It may be continuous (five days per week 
without interruption ) or given in a split course (every other week or three 
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weeks on with a one or two weeks break followed by three more weeks of 
treatment). 
PROGNOSTIC FACTORS AND PATTERNS OF FAILURE: 
SQUAMOUS CELL CARCINOMAS: 
Several end points, including rates of survival, disease free survival, 
distant metastasis, loco regional control ,neck control and primary 
occurrence, have been used to evaluate the outcome of patients with 
cervical SCC metastasis from unknown primary numerous clinical and 
physical factors associated with these endpoints have been reported. 
Selection bias is unavoidable for example ipsilateral irradiation is typically 
administered for advanced disease or poor performance status patients, 
whereas  surgery is performed in early stages squamous cell Carcinoma. 
The majority of information available in the literature is referred to 
SCC.  The nodal status is considered the most important prognostic  factor 
infact  the prognosis seems comparable to that observed in patients with 
overt primary and  similar nodal stage. For patients treated with neck 
dissection, the prognostic factors include the number of lymphnodes, 
grading and  extracapsular extension over the last 30 years, probably due 
to better pre  treatment evaluation and more effective therapy, neck control 
and primary occurrence have improved in Head and Neck CUP patients. 
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The pattern of failure depends on the treatment applied. According 
to some authors, in early stages neck dissection alone and radiotherapy 
alone are equivalent and provide satisfactory nodal control after extensive 
radiotherapy, the predominant patterns of relapse include neck recurrence 
and distance metastases. 
The effectiveness of radiotherapy is illustrated by the fact that the 
risk of emergence of a primary lesion after extensive irradiation is similar 
to the occurence  of second tumour in a patient with overt head and neck 
cancer the median time to the  occurrence of subsequent primary is about 
21 months and the most common sites are the oral cavity, oro 
annasopharynx, supraglottis and lung several authors observed poor 
prognosis after a subsequent detection of the primary lesions in the case of 
cervical lymph node metastasis from SCC; Median survival of 15 months 
and 5 year survival of 20% after the detection of the primary other authors  
attributed poor  outcomes to nodal relapse, but not to primary occurrence, 
in some series tumours arising later than 5 years after the primary 
treatment were classified as second primaries, whereas in others, they 
were considered to be site of  origin the predominant site of relapse after 
radiotherapy includes neck, followed by distant metastasis. The crude risk 
of either nodal recurrence or distant metastasis is atleast two fold higher 
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than the risk of a developing a mucosal primary. The benefit from 
extensive radiotherapy to the mucosa and bilateral neck should weighed 
against acute and late morbidity (xerostomia, dysphagia etc.) and the 
difficulties in re-irradiation in the case of subsequent primary emergence. 
Several retrospective studies show that ipsilateral neck radiotherapy is 
correlated with a primary occurrence rate similar to that observed after 
extensive radiotherapy, for these reasons many authors perform an 
ipsilateral radiotherapy to the involved neck side surgery (planned neck 
dissection) performed after radiotherapy showed persistence of nodal 
disease in upto 44% of patients. Such a sequence was associated with 
poorer survival and with higher post operative morbidity as compared to 
surgery followed by radiotherapy. These outcomes may however be 
related to selection bias, as radiotherapy is typically attempted in patients 
with advanced, inoperable neck disease amichetti et al., applied local 
microwave hyperthermia and radiotherapy (median 70Gy to bilateral neck 
and potentially primary sites) in a group of 15 patients with locally 
advanced squamous cell neck carcinoma from unknown  primary. Overall 
response rate was 87% but   actual 5 year local control and overall survival 
rates were 65% and 29% respectively. Both acute and late toxicties were 
moderate, however long follow up and larger patients groups are needed to 
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evaluate the role of this approach. Patients presenting with poor 
performance status, very extensive nodal involvement, distant metastases 
or bilateral low neck involvement are usually approached with paliative 
irradiation. Palliative  radiotherapy, independently of the radiotherapy 
regimen, is associated with an objective response rate of 65%, the 
symptomatic response rate of 57% at one year, and 25% one year survival; 
these results are similar to those  obtained with palliative chemotherapy, 
which would likely be more toxic and more expensive. 
UNDIFFERENTIATED AND POORLY DIFFERENTIATED 
CARCINOMAS: 
Results are similar to those of overt undifferentiated naso 
pharyngeal carcinoma 
ADENOCARCINOMA: 
Prognosis of adenocarcinoma from unknown origin is poor, 
especially when level  IV is involved. Due to  their rarity are generally  
reported considering all metastatic sites. 
FOLLOW UP: 
Follow up examinations are scheduled on an individual basis 
determined by the risk of recurrence, to survey for the appearance of the 
primary tumour, to deal with morbidity from treatment and with 
57 
 
comorbidity not directly related to the cancer itself during radiation 
therapy periodic examinations by the head and neck surgeon my be 
necessary in patients experiencing difficulty with nutritional intake, 
airway or pain control after all treatment is completed periodic 
examinations by the radiation oncologist and a dentist in patients that 
received radiation therapy are  recommended. 
Thyroid function tests should be monitored if the patient received 
radiation to the lower neck since upto 30% of patients may develop 
subclinical or overt radiation induced hypothyroidism 
Oncological Checks Depend on Histology:  
SCC Adenocarcinoma  
Clinical and fibrescopic check every two months in the first year, 
every 4 months for second and third year, then every six months PET once 
a year Additional exams at the discretion of the physician. Lymphoma and 
Thyroid carcinoma based on specific protocols Neck metastasis from other 
sited (eg, breast, prostate, colon):a follow up according to clinical and 
fibrescopic ENT evaluation 
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NECK DISSECTION 
 
Introduction 
 
Cancers in the head and neck region commonly metastasize to 
cervical lymph nodes. The term neck dissection refers to a surgical 
procedure in which the fibro fatty contents of the neck are removed for the 
treatment of cervical lymphatic metastases. Neck dissection is most 
commonly employed in the management of cancers of the upper 
aerodigestive tract. It is also used for malignancies of the skin of the head 
and neck area, the thyroid, and the salivary glands. 
  
Radical neck dissection has been the standard surgical procedure for 
treatment of metastatic neck cancer since its description by Crile in 1906. 
Until only a couple of decades ago, it was widely used as an elective 
procedure for occult neck disease and as a therapeutic procedure for 
clinically manifest nodal metastases. However, in the last 2 decades, a 
shift toward the use of more conservative surgical procedures has 
occurred, arising from the realization that many non lymphatic structures 
in the neck, as well as certain lymph node groups, may be preserved in 
certain situations without compromising disease control. 
 
The current classification of neck dissections by the American 
Academy of Otolaryngology / Head and Neck Surgery is based on the 
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following governing principles: 
 
 Radical neck dissection is the standard basic procedure for cervical 
lymphadenectomy, and all other procedures represent one or more 
modifications of this procedure. 
 
 When modification of the radical neck dissection involves 
preservation of one or more non lymphatic structures, the procedure 
is termed a modified radical neck dissection. 
 
 When the modification involves one or more lymph node groups 
that are routinely removed in the radical neck dissection, the 
procedure is termed a selective neck dissection. 
 
 When the modification involves removal of additional lymph node 
groups or non lymphatic structures relative to the radical neck 
dissection, the procedure is termed an extended radical neck 
dissection 
 
This classification was developed by the Committee for Head and 
Neck Surgery and oncology, American Academy of Otolaryngology – 
Head and Neck surgery, Courtesy of the Archives of Otolaryngology – 
Head and Neck Surgery. 
 
¨ Radical neck dissection 
 
¨ Modified radical neck dissection 
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¨ Selective neck dissection 
 
o Supraomohyoid type 
 
o Lateral type 
 
o Posterolateral type 
 
o Anterior compartment type 
 
¨ Extended radical neck dissection. 
 
 
 
Radical neck dissection 
 
Originally described by Crile in 1906, this procedure is an en bloc 
clearance of all fibro fatty tissue from one side of the neck, including the 
lymph nodes from level I through V, lymph nodes. Surrounding the tail of 
the parotid gland, the spinal accessory nerve, the internal jugular vein, and 
the sternocleidomastoid muscle. It does not include the removal of the 
postauricular, suboccipital, perifacial buccinator, retropharyngeal and 
central compartment nodes. 
 
Previously used for neck disease of any stage, from microscopic to 
bulky nodal disease, this procedure now finds its application limited to 
patients with advanced neck disease or with gross extracapsular spread to 
the spinal accessory nerve, sternomastoid muscle and the internal jugular 
vein. 
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Modified radical neck dissection 
 
This operation involves the removal of the same lymph node groups 
as the radical neck dissection (levels I through V) but requires 
preservation of 1 or more of the 3 non lymphatic structures; the spinal 
accessory nerve, the internal jugular vein, and the sternomastoid muscle. 
 
Modified neck dissection is indicated in cases with clinically 
palpable metastatic neck disease. Conversion to the radical neck dissection 
becomes necessary when gross involvement of the nerve, vein and muscle 
is present, although the involvement of all 3 is unusual, except in very 
advanced (N3) disease. 
 
Comprehensive neck dissection is a term that frequently appears in 
the literature. This refers to any type of neck dissection that involves 
removal of lymph nodes from levels I through V and corresponds, 
therefore, to radical and modified radical neck dissections according to the 
Academy’s classification. 
Selective neck Dissection 
 
This term refers to a type of neck dissection in which certain lymph 
node groups in the neck are preserved while others are removed. Included 
in this category are supraomohyoid neck dissection, lateral neck 
dissection, anterior compartment neck dissection, and posterolateral neck 
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dissection. 
Supraomohyoid neck dissection 
 
Selective removal of the level I, II and III lymph nodes is called 
supraomohyoid neck dissection. The operation includes the resection of 
soft tissue in the submental triangle, along with the submandibular triangle 
contents, including the submandibular gland and the fibrofatty tissue along 
the internal jugular vein in the upper 2 levels. The dissection contents 
include the fascia covering the medial aspect of the sternomastoid muscle; 
the muscle itself is retracted laterally and preserved. These neck contents 
are peeled off from the internal jugular vein and from around the 
accessory nerve, sparing these structures. 
Supraomohyoid neck dissection is indicated for the prophylactic 
treatment of occult neck disease in cancers known to metastasize to this 
group of nodes, i.e cancers of the oral cavity. Application of this type of 
the neck dissection to treat clinically positive nodes remains controversial. 
If this operation is performed for N+ disease, including level Ic in the 
dissection may be prudent. 
Lateral Neck dissection 
 
Selective removal of the soft tissues containing the level, II, III and 
IV lymph nodes along the internal jugular vein is called lateral or 
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anterolateral neck dissection. The spinal accessory nerve, sternomastoid 
muscle, and internal jugular vein are spared in this operation. 
 
This operation is commonly performed for the prophylactic 
treatment of occult disease in patients with primary cancers in the 
oropharynx, hypopharynx, or larynx. 
 
Both the supraomohyoid and the lateral neck dissections may need 
to be performed on both sides in patients whose primary tumors are 
located close to or across the midline. Cancers of the central tongue, floor 
of the mouth, low lip, and supraglottic larynx are known to metastasize 
bilaterally. 
Anterior compartment neck dissection 
 
This operation involves excision of the level VI lymph nodes. The 
procedure is indicated for the treatment of cancers of the thyroid gland, 
hypopharynx, cervical trachea, cervical esophagus, and subglottic larynx. 
The boundaries of the dissection are the hyoid hone superiorly, the 
suprasternal notch inferiorly, and the carotid sheaths on either side. 
Hyopoparathyroidism may be a disabling complication if care is not taken 
to identify and preserve the parathyroid glands, and injury to the 
parathyroid blood supply is a risk with this procedure. Excising and 
reimplanting the glands into the sternomastoid or pectoralis major muscles 
64 
 
may be necessary. Alternatively, the dissection may be limited to one side 
if the lesion is not close to the midline, particularly if radiation therapy can 
be administered postoperatively. 
Posterolateral neck dissection 
 
Posterolateral neck dissection was initially described by Rochin in 
1962 and later modified and popularized by Geopfert et al for use in 
patients with cutaneous malignancies of the scalp and postauricular and 
suboccipital regions. Unlike all other neck dissections, this operation is 
performed with the patient in the lateral decubitus position and consists of 
an en bloc removal of the lymph nodes in the suboccipital, postauricular, 
and upper, middle and lower jugular nodes, along with posterior triangle 
nodes situated superior to the accessory nerve. Although the original 
description included sacrifice of the accessory nerve, internal jugular vein, 
and a portion of the trapezius muscle, Diaz et al from the MD Anderson 
Cancer centre showed in 1996 that preserving these non lymphatic 
structures dies not increase the failure rate of this operation. 
Extended neck dissection 
 
In cases of advanced neck disease, certain lymphatic or non 
lymphatic structures, not routinely included in the aforementioned neck 
dissections, may have to be removed. Extended neck dissection is the term 
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used to describe these procedures. Retropharygeal lymph nodes, the 
hypoglossal nerve, portions of the prevertebral musculature, or the carotid 
artery are some of the structures that may occasionally have to be excised 
in order to obtain negative margins. 
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MATERIALS AND METHODS 
 
 
During a period of 8 months from January 2017 to August 2017 
datas were collected from 43 patients who were admitted to the surgical 
units of Kilpauk medical college hospital with a diagnosis of cervical 
lymphadenopathy. Children below 12 years of age were not included. All 
patients with known primaries were excluded from the study. Likewise 
patients with lymphatic malignancies were excluded. Patients with 
infective pathology and non specific lymphadenitis were also excluded 
from the study. A total of 43  patients were finally included in the study. 
 
The workup for all the patients on admission was a follows: 
 
History 
 
A detailed history was obtained from all patients, attention was 
focused on onset of swelling, duration of swelling, rate of growth of the 
swelling ,associated pain, pressure and obstructive symptoms like 
dizziness (carotid tree involvement),shooting pain over arm (brachial 
plexus involvement), difficulty in breathing ,difficulty in swallowing, 
change in voice were elicited. History of otalgia, aural fullness, nasal 
congestion and epistaxis were also obtained. Social history including 
occupational hazards like exposure to ultraviolet light, industrial 
chemicals and metals were obtained. Information concerning alcohol 
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consumption and tobacco product usage were obtained. History of any 
irradiation to the head and neck in the past and past treatment of other 
head and neck carcinoma were elicited. Any associated illness were also 
noted. 
Physical examination 
 
The lymph node was taken significant if the size was more than 
1cm, spherical rather than ovoid in shape, hard in consistency. 
 
Note was made of the side and the triangle of the neck involved, the 
total number of palpable nodes, the groups involved, size, consistency, 
presence of tenderness, fixity to skin as well as deeper structures, presence 
of any contralateral nodes and the N stage of the nodes. 
 
Nodes deep to the sternocleidomastoid were included in anterior 
cervical triangle as the classical description of the cervical triangle 
excludes the nodes deep to the sternomastoid muscles from either of the 
two triangles. Midline nodes were considered as homolateral nodes. In all 
instances the clinical impression of the first observer was confirmed by at 
least one another observer. 
 
The physical examination was then focused on the head and neck, 
beginning with inspection and palpation of the skin. The scalp and 
external ears were inspected in detail. All zones of the neck were palpated 
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thoroughly in an effort to find additional lymphadenopathy or masses. The 
nasal vestibule, oral cavity and oropharynx were thoroughly inspected. 
Because submucosal lesions are not typically evident with visual 
inspection, manual palpation of the oral cavity and the oropharynx were 
done. Special attention was paid to the base of the tongue during 
palpation. Special focus was given for any thyroid swelling, breast, 
respiratory system, abdomen, and genitalia were examined. 
 
Chest radiograph was done for all patients. For patients with suspicious 
lesions on chest radiograph, CT scan of the chest was done. Bronchoscopy 
was done for all patients 
 
Indirect laryngoscopy was done for all patients particularly looking 
for any growth or mucosal abnormalities in nasopharynx, oropharynx and 
larynx. 
 
Upper gastrointestinal endoscopy was done for all patients. 
Ultrasound abdomen was done for all patients. 
 
FNAC was done from the nodes. The histopathological report was 
expressed in three grades –Well differentiated, moderately differentiated 
and poorly differentiated carcinoma, adenocarcinoma and papillary 
carcinoma thyroid. 
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RESULTS OF THE STUDY 
 
1. AGE DISTRIBUTION 
 
Incidence of age in nodal metastasis of neck with unknown primary 
 
Table - 1 
 
Age in years No of cases out of 43 Percentage % 
10-20 1 2 
20-30 2 5 
30-40 2 5 
40-50 7 16 
50-60 20 46 
60-70 8 19 
70-80 2 5 
> 80 1 2 
 
Most cases presented around 40-70years. of them the presentation 
is more in 50-60 years of age 
2. SEX DISTRIBUTION OF THE NODES 
 
Sex distribution of the nodes 
 
 TABLE - 2  
sex No of cases out of 43 Percentage% 
Male 37 86 
Female 6 14 
 
Out of the 43 patients with neck secondaries with unknown primary 
37 (86%) patients were male, 6 (14%) patients were female. 
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The following were the histopathological distribution among males and 
females; 
TABLE - 3  
   
Histolopathology males Females 
Poorly diff carcinoma 22 3 
Mod diff carcinoma 5 1 
Well diff carcinoma 8 1 
Adenocarcinoma 2 1 
 
 
3. TOPOGRAGHICAL DISTRIBUTION OF NODAL 
METASTASES 
 
Analysis of topographical distribution of cervical node metastasis 
from various sites revealed the following patterns. 
Of this 43 patients one patient (2.3%) presented with more than one 
group of nodes. it was involving the level II and level III. 
One patient (2.3%)  presented with bilateral nodes. and involving 
level II, level III and level IV. 
41patients (95.34%) presented with only single group of nodes. The 
following pattern was noted in these patients. 
Out of the 41 patients who had a single group of nodes 96% had the 
nodes in level II and level III. 
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Topographical distribution of nodes 
 
TABLE - 4 
Lymph node levels No of patients out of Percentage 
 41  
Level I 0 0 
Level II 28 68.29 
Level III 11 26.82 
Level IV 1 2.43 
Level V 1 2.43 
Level VI 0 0 
 
Of the 41 patients who presented with single node only, most of 
them were in level II and level III 
No patients presented with level I and level VI nodes with an 
unknown primary. 
4. SIDE OF DISTRIBUTION OF THE NODES 
 
 
 TABLE - 5  
 Side distribution of nodes  
    
Side of the nodes 
No of patients out of 
43  Percentage 
Left 28  65 
Right 15  35 
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Of the 43 patients (15patients-35%) presented with right sided 
nodes.28 patients (65%) presented with left sided nodes 
The following are the histopathological distribution of nodes 
 
TABLE - 6 
 
Histopatholgy Right Left 
Poorly diff carcinoma 7 18 
Mod diff carcinoma 3 3 
Well diff carcinoma 4 5 
Adenocarcinoma 1 2 
 
 
5. HISTOPATHOLOGICAL ANALYSIS OF THE NODAL 
METASTASIS 
 
 
Out of the 43 patients included in the study 25 patients(58%) had 
poorly differentiated carcinomatous deposit .9 patients (21%) had 
metastatic deposit from squamous cell carcinoma. 
 
The histopathological analyses are presented in the following 
 
TABLE - 7 
 
 
Histology No of patients Percentage 
Poorly differentiated metastatic 
carcinoma 25 58 
Moderately differentiated metastatic 6 14 
Carcinoma   
Metastatic deposit from squamous cell 9 21 
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Carcinoma   
Metastatic deposit from 
adenocarcinoma 3 7 
 
TREATMENT 
 
All patients with operable nodes were treated with radical neck 
dissection. Those patients with extracapsular spread and multiple nodes 
were given radiotherapy and chemotherapy. For patients with operable 
bilateral nodes bilateral radical neck dissection was done in intervals. 
 
For patients with inoperable masses chemoradiation was given. 
Combination chemotherapy with cisplatin (Days 1- 2) and 5-FU (for Days 
1- 5) was regimen given for all the patients. 
Radiotherapy was given for 33 fractions of 300cGY per day for 5 
days/week. A total dose of 6600 cGy was given. Palliative radiotherapy 
was given for advanced disease with 10 fractions of 200cGY per day. A 
total of 2000 cGY was given. 
   
During the 8 months study no subsequent primary site was identified 
in all the patients. 
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DISCUSSION 
 
 
Squamous cell carcinoma of the head and neck is the most common 
malignancy in India. Treating a patient with malignant cervical 
lymphadenopathy poses a challenge to the clinician in finding out the 
primary site. 
 
 The incidence of malignant cervical lymphadenopathy  was 2 % of 
all cancers. 
 The male to female ratio is 6:1 in our study, which matches with the 
 
 world average. The higher incidence in the males could be due to 
increased exposure to tobacco products and occupational hazards 
than females. 
 81% of the patients presented between 40- 70 years. Highest 
incidence was seen between 50 – 60 years. 
 
 58% of the patients had poorly differentiated carcinoma and 21% of 
the patients had well differentiated squamous cell carcinoma. This is 
 in contrast to the western literature where squamous cell carcinoma 
accounts for 30% -50% and poorly differentiated carcinoma 
accounts for 25%. This could imply that more aggressive cancers are 
seen in our part of the world. This could be due to variable disease 
process or the various pathogenic factors playing a part. 
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 2.3% of the patients presented with bilateral nodes, which means the 
most probable site of primary could be in the midline structures like 
base of tongue, nasopharynx and supraglottis. 
 
 In our study we also noted a higher incidence on the left side(65%), 
when compared to the right side(35%). Are they due to keeping the 
tobacco products more commonly on the left is to be evaluated by 
further studies. 
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CONCLUSION 
 
The unknown primary tumour presents several clinical dilemmas 
including how to find the primary site and, if the site is never found, to 
direct treatment. 
The incidence of patients with an unknown primary site is low 
overall because of the effectiveness of clinical examination coupled with 
pan endoscopy and directed biopsies. Modern Radiograghic technology 
including CT/MRI, PET scan, and  recently, PET-CT may be of value in 
some cases. As these diagnostic methods become more refined there may 
eventually be no patients with an unknown primary tumour. Of course, 
once the primary site is identified, treatment of this patients can become 
much more specifically directed. We hope that in future the unknown 
primary site will no longer be a featured entry. 
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PROFORMA 
 Name           Age/sex               IP.No:               phone No:     
 Unit                                           Address       
Date of admission:      Date of discharge:     occupation   
PRESENTING COMPLAINTS:  
ANY SIGNIFICANT PRESENT HISTORY  
PAST HISTORY & TREATMENT HISTORY  
PHYSICAL EXAMINATION  :  
     Level of  consciousness  
     orientation   
     Hydration status  
     anaemia ,jaundice,clubbing,pedal edema   
Vitals 
 EXAMINATION OF NECK:   
 Other system ex.;  CVS/RS    ABDOMEN   CNS  P/R   P/V  
                                  External genitalia  
 INVESTIGATIONS:  
 BLOOD ;    complete hemogram 
                     Renal function test.,          
                     Serum electrolytes  
                     Liver function test  
  
Chest x ray 
USG NECK  
FNAC  
 TRU CUT BIOPSY 
  CT SKULL BASE TO MEDIASTINUM 
 PAN ENDOSCOPY AND TRIPLE ENDOSCOPY 
 GUIDED BIOPSY  
 USG ABDOMEN  
 CECT ABDOMEN 
 PET - CT 
TYPES OF THERAPY 
1. Surgery 
2. Chemotherapy 
3. Radiotherapy 
  
 
MASTER CHART 
Column 1 Column 2 Column 3 Column4 Column 5 Column 6 Column 7 Column 8 Column 9 Column 10 Column 11 Column 12 Column 13 Column 14 
Name Age Sex Ip no Ses Smoking Alcoholism Familyhist 
Neckswelling 
Usgneck ct 
neck 
 Ct neck Fnac Hpe Treatment 
Raman 60 male 87229 low SES yes yes no yes done done done scc surgery /RT 
Deswan 52 male 16927 low SES yes yes no yes done done done scc surgery /RT 
Govindan 71 male 85664 low SES yes no no yes done done done scc surgery /RT 
Rehman 55 male 88489 low SES yes yes no yes done done done scc surgery /RT 
Mari 54 male 2201 low SES yes yes no yes done done done adeno surgery /RT 
Vasu 62 male 29117 low SES yes yes no yes done done done scc chemo RT 
Shane 41 male 1377 low SES yes no no yes done done done scc surgery /RT 
Rajendran 54 male 75831 low SES yes yes yes yes done done done scc surgery /RT 
Chandran 57 male 84231 low SES yes yes no yes done done done scc surgery /RT 
Murali 64 male 82985 low SES yes yes no yes done done done scc surgery /RT 
Kannan 82 male 102346 low SES yes no no yes done done done adeno surgery /RT 
Kantha 56 female 105634 low SES no no no yes done done done scc chemo RT 
Mani 45 male 98456 low SES yes yes yes yes done done done scc chemo RT 
Krishnan 56 male 78654 low SES yes yes no yes done done done scc surgery /RT 
Vanjikodi 55 female 97345 low SES no no no yes done done done scc surgery /RT 
Thangam 67 female 98876 low SES no no no yes done done done scc surgery /RT 
Kathirvel 52 male 87234 low SES yes yes no yes done done done scc RT 
Rajan 57 male 90867 low SES yes yes no yes done done done scc surgery /RT 
Siva 48 male 67543 low SES yes yes no yes done done done scc surgery /RT 
Ranjitham 56 female 45632 low SES no no no yes done done done scc surgery /RT 
Nanjamma 53 female 45670 low SES no no no yes done done done scc surgery /RT 
Saravanan 68 male 23145 low SES yes yes no yes done done done scc surgery /RT 
Durai 57 male 453216 low SES yes yes no yes done done done scc surgery /RT 
Palani 58 male 87234 low SES yes yes yes yes done done done scc surgery /RT 
Perumal 84 male 56342 low SES yes yes no yes done done done scc surgery /RT 
Pandu 67 male 105326 low SES yes yes no yes done done done scc surgery /RT 
Ahmed 45 male 42980 low SES yes yes no yes done done done adeno surgery /RT 
Shanmugam 59 male 815113 low SES yes no no yes done done done scc chemo RT 
Chandru 60 male 107744 low SES yes yes no yes done done done scc chemo RT 
Rajee 50 male 6993 low SES yes yes no yes done done done scc surgery /RT 
Hussain 65 male 99653 low SES no no no yes done done done scc surgery /RT 
 
